194 related articles for article (PubMed ID: 20500856)
1. Plasmodium falciparum proteome changes in response to doxycycline treatment.
Briolant S; Almeras L; Belghazi M; Boucomont-Chapeaublanc E; Wurtz N; Fontaine A; Granjeaud S; Fusaï T; Rogier C; Pradines B
Malar J; 2010 May; 9():141. PubMed ID: 20500856
[TBL] [Abstract][Full Text] [Related]
2. A proteomic glimpse into the effect of antimalarial drugs on Plasmodium falciparum proteome towards highlighting possible therapeutic targets.
Dousti M; Manzano-Román R; Rashidi S; Barzegar G; Ahmadpour NB; Mohammadi A; Hatam G
Pathog Dis; 2021 Jan; 79(1):. PubMed ID: 33202000
[TBL] [Abstract][Full Text] [Related]
3. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum.
Dahl EL; Shock JL; Shenai BR; Gut J; DeRisi JL; Rosenthal PJ
Antimicrob Agents Chemother; 2006 Sep; 50(9):3124-31. PubMed ID: 16940111
[TBL] [Abstract][Full Text] [Related]
4. Absence of association between Plasmodium falciparum small sub-unit ribosomal RNA gene mutations and in vitro decreased susceptibility to doxycycline.
Gaillard T; Wurtz N; Houzé S; Sriprawat K; Wangsing C; Hubert V; Lebras J; Nosten F; Briolant S; Pradines B;
Malar J; 2015 Sep; 14():348. PubMed ID: 26377329
[TBL] [Abstract][Full Text] [Related]
5. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites.
Bullard KM; Broccardo C; Keenan SM
Malar J; 2015 Apr; 14():147. PubMed ID: 25879664
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of Plasmodium falciparum schizonts reveals heparin-binding merozoite proteins.
Zhang Y; Jiang N; Lu H; Hou N; Piao X; Cai P; Yin J; Wahlgren M; Chen Q
J Proteome Res; 2013 May; 12(5):2185-93. PubMed ID: 23566259
[TBL] [Abstract][Full Text] [Related]
7. Apicoplast Import Protein Tic20 A Promising Therapeutic Molecular Target for Plasmodium falciparum: An In Silico Approach for Therapeutic Intervention.
C P K Srimath-Tirumala-Peddinti R; Kusuma SS; Nammi D; Neelapu NRR
Infect Disord Drug Targets; 2017; 17(3):199-222. PubMed ID: 28595540
[TBL] [Abstract][Full Text] [Related]
8. The
Henrici RC; Edwards RL; Zoltner M; van Schalkwyk DA; Hart MN; Mohring F; Moon RW; Nofal SD; Patel A; Flueck C; Baker DA; Odom John AR; Field MC; Sutherland CJ
mBio; 2020 Feb; 11(1):. PubMed ID: 32098816
[TBL] [Abstract][Full Text] [Related]
9. Proteomic approaches to studying drug targets and resistance in Plasmodium.
Cooper RA; Carucci DJ
Curr Drug Targets Infect Disord; 2004 Mar; 4(1):41-51. PubMed ID: 15032633
[TBL] [Abstract][Full Text] [Related]
10. Absence of correlation between ex vivo susceptibility to doxycycline and pfteQ-pfmdt gene polymorphism in French Guiana.
Mura M; Briolant S; Donato D; Volney B; Pelleau S; Musset L; Legrand E
Malar J; 2015 Jul; 14():286. PubMed ID: 26206143
[TBL] [Abstract][Full Text] [Related]
11. Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort.
Laochan N; Zaloumis SG; Imwong M; Lek-Uthai U; Brockman A; Sriprawat K; Wiladphaingern J; White NJ; Nosten F; McGready R
Malar J; 2015 May; 14():221. PubMed ID: 26017553
[TBL] [Abstract][Full Text] [Related]
12. Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria.
Makanga M; Bray PG; Horrocks P; Ward SA
Proteomics; 2005 May; 5(7):1849-58. PubMed ID: 15832369
[TBL] [Abstract][Full Text] [Related]
13. [Transport proteins as drug targets in Plasmodium falciparum. New perspectives in the treatment of malaria].
Ellekvist P; Colding H
Ugeskr Laeger; 2006 Mar; 168(13):1314-7. PubMed ID: 16579884
[TBL] [Abstract][Full Text] [Related]
14. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets.
Mogire RM; Akala HM; Macharia RW; Juma DW; Cheruiyot AC; Andagalu B; Brown ML; El-Shemy HA; Nyanjom SG
PLoS One; 2017; 12(10):e0186364. PubMed ID: 29088219
[TBL] [Abstract][Full Text] [Related]
15. The use of proteomics for the identification of promising vaccine and diagnostic biomarkers in
Mansouri R; Ali-Hassanzadeh M; Shafiei R; Savardashtaki A; Karimazar M; Anvari E; Nguewa P; Rashidi S
Parasitology; 2020 Oct; 147(12):1255-1262. PubMed ID: 32618524
[TBL] [Abstract][Full Text] [Related]
16. UK malaria treatment guidelines.
Lalloo DG; Shingadia D; Pasvol G; Chiodini PL; Whitty CJ; Beeching NJ; Hill DR; Warrell DA; Bannister BA;
J Infect; 2007 Feb; 54(2):111-21. PubMed ID: 17215045
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined drug treatments on Plasmodium falciparum: In vitro assays with doxycycline, ivermectin and efflux pump inhibitors.
Nodari R; Corbett Y; Varotto-Boccazzi I; Porretta D; Taramelli D; Epis S; Bandi C
PLoS One; 2020; 15(4):e0232171. PubMed ID: 32324826
[TBL] [Abstract][Full Text] [Related]
18. Large-scale differential proteome analysis in Plasmodium falciparum under drug treatment.
Prieto JH; Koncarevic S; Park SK; Yates J; Becker K
PLoS One; 2008; 3(12):e4098. PubMed ID: 19116658
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.
Qidwai T; Khan F
Chem Biol Drug Des; 2012 Aug; 80(2):155-72. PubMed ID: 22487082
[TBL] [Abstract][Full Text] [Related]
20. PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria.
Gaillard T; Briolant S; Houzé S; Baragatti M; Wurtz N; Hubert V; Lavina M; Pascual A; Travaillé C; Le Bras J; Pradines B;
Malar J; 2013 Nov; 12():414. PubMed ID: 24225377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
